Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto
Date
2020
Type:
Article
item.page.extent
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
The financial coverage granted by law in Chile for patients with psoriatic
arthritis who require biological treatment is of paramount importance and a
great advance. However physicians must be knowledgeable about the advantages
and limitations of this therapy. The challenge of clinicians is to choose the drug
with the greater odds of achieving therapeutic success, with less adverse events
and lower costs for our health system. This article aims to help doctors to select
the best biological treatment for a specific patient, trying to optimize its effectiveness, minimizing adverse effects, always looking for an efficient use of resources.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Revista Médica de Chile, 2020, vol.148: 657-664
Keywords
Arthritis, Psoriatic, Biological Therapy, Spondylitis, Ankylosing